Nikko Asset Management Americas’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
Other funds holding IOVA
MFM
PA
ACA
Nikko Asset Management Americas's IOVA Position: Q3 2023 in Review
Nikko Asset Management Americas sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 2,490,600 shares — an estimated $17.5M sold.
Nikko Asset Management Americas first reported a position in IOVA in Q1 2019 and held it in 18 quarters. The position peaked at $205M in Q4 2020. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.
- Nikko Asset Management Americas reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
- Nikko Asset Management Americas sold 2,490,600 Iovance Biotherapeutics shares in Q3 2023, an estimated $17.5M.
- Nikko Asset Management Americas first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 18 quarters.
- Nikko Asset Management Americas's Iovance Biotherapeutics position peaked at $205M in Q4 2020.
- 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.
Based on Nikko Asset Management Americas's 13F filing for Q3 2023, filed 9 Nov 2023.